Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion

Indian Journal of Urology

Volumn 28, Issue 4, 2012, Pages 424-426

  Eldefrawy, Ahmed ^a   Soloway, Mark S ^a   Katkoori, Devendar ^a   Singal, Rakesh ^a   Pan, David ^a   Manoharan, Murugesan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; bladder cancer; chemotherapy; completion; neoadjuvant; radical cystectomy

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER STAGING; CYSTECTOMY; DRUG TOLERABILITY; FEMALE; HUMAN; HYDRONEPHROSIS; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUSCLE INVASIVE BLADDER CANCER; PERIOPERATIVE PERIOD; PROSTATIC STROMAL INVASION; RETROSPECTIVE STUDY; URINARY DIVERSION;

EID: 84873444321     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.105756     Document Type: Article

References (13)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Malkowicz SB, van Poppel H, Mickisch G, Pansadoro V, Thuroff J, Soloway MS, et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007;69:3-16
3. Manoharan M, Katkoori D, Kishore TA, Kava B, Singal R, Soloway MS. Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed. BJU Int 2009;104:1646-9
4. Manoharan M, Ayyathurai R. Radical cystectomy for urothelial cancer of the bladder: Contemporary advances. Minerva Urol Nefrol 2007;59: 99-107
5. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009;55:348-58
6. Herr HW. Neoadjuvant chemotherapy: A new treatment paradigm for muscle-invasive bladder cancer. Eur Urol 2009;55:303-5; discussion 5-6
7. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815-25
8. Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, et al. Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the Medicare population. Urology 2005;65:1118-25
9. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 2007;178:451-4
10. Fairey AS, Jacobsen NE, Chetner MP, Mador DR, Metcalfe JB, Moore RB, et al. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: Results from the Alberta Urology Institute Radical Cystectomy database. J Urol 2009;182:85-92; discussion 3
11. Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: A high-Volume tertiary cancer center experience. Eur Urol 2009;55:177-85
12. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-Analysis. J Urol 2004;171:561-9
13. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007;177:437-43